Slide 1: Health-Related Quality of Life in Patients with R/R CTCL Treated by Lacutamab
Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma Treated by Lacutamab: Patient-Reported Outcomes from the Phase 2 TELLOMAK Trial Publication Number: 466 Submission ID: 194796
Slide 2: Authors and Affiliations
Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma Treated by Lacutamab: Patient-Reported Outcomes from the Phase 2 TELLOMAK Trial Martine Bagot1, Youn H. Kim2, Caroline Ram-Wolff1, Stéphane Dalle3, Neha Mehta-Shah4, Auris O Huen5, Brian Poligone6, Pier Lui
Slide 3: Introduction: TELLOMAK trial and lacutamab
Introduction TELLOMAK trial - NCT03902184 LACUTAMAB • Lacutamab is in development for the treatment of T-cell Lymphoma including CTCL (Sezary Syndrome [SS] and Mycosis • Lacutamab is a first in class depleting Fungoides [MF]) in the Phase 2 TELLOMAK study: antibody targeting KIR3DL2. Cohort 1 SS (N~
Slide 4: Quality of Life: Rationale and Assessment in TELLOMAK
Quality of Life Rationale Quality of Life in TELLOMAK • Patients with advanced and heavily • Assessments were performed at baseline, W5 then Q8W until pretreated relapsed/refractory CTCL have week 45 then Q12W, and reported with descriptive statistics, poor health-related quality of life (HRQoL) foc
Slide 5: TELLOMAK - Baseline Characteristics
TELLOMAK - Baseline Characteristics * SS DCO 01MAY23 **MF DCO 13OCT23 Patient Characteristics Cohort SS* N=56 Cohorts MF** N=107 Age in years, median (range) 69 (42-86) 62 (19-82) Male, n (%) 34 (60.7) 72 (67.3) Stage at screening, I-II n (%) 0 (0.0) 82 (76.6) III-IV n (%) 56 (100) 25 (23.4) T4, n (
Slide 6: Pruritus in Sezary Syndrome
VAS Pruritus in Sezary Syndrome Severe Moderate • Pruritus elevated at baseline (VAS 6.2) with 25% of patients having very severe score Mild VAS>8.2 • Early decrease of itch intensity starting from W5 • Deep and clinically meaningful decrease ≥2 points in VAS scale from W13 (VAS<4, mild pruritus) ma
Slide 7: Skindex-29 in SS
Skindex-29 Skindex-29 in SS Severe 44 Moderate • Severe global score at baseline (52.7) 32 Mild 25 Low • Early decrease to moderate score starting from W5 • Continuous and deep decrease to mild or low score maintained over time (i.e. 27.8 at W13 then 14.4 at W45) • Improvement is observed not only i
Slide 8: Skindex-29 in SS and by domain
Skindex-29 – Global Score Skindex-29 in SS and by domain • Severe global scores for most (61.5%) of the patients at baseline decreasing down to <20% of patients from W29 and none from W81 • Severe scores reported in all 3 Symptoms Functioning Emotions domains for majority of patients at baseline, wi
Slide 9: Pruritus in Mycosis Fungoides
VAS Pruritus in Mycosis Fungoides Severe Moderate • Pruritus elevated at baseline (VAS=6) with 25% of patients having very severe score Mild of VAS>8.2 • Early and slight improvement of itch intensity from W5 (VAS=5) • Continuous and deeper clinically meaningful decrease from W37 (VAS<4, mild prurit
Slide 10: Skindex-29 in MF
Skindex-29 Skindex-29 in MF Severe 44 Moderate • Severe global score at baseline (56.3) 32 Mild 25 Low • Early slight decrease starting from W5 (46.3) • Continuous and deeper decrease to moderate score from W13 (eg 38.8 at W29) then low score • Improvement is observed earlier in responder patients a
Slide 11: Skindex-29 in MF
Skindex-29 – Global Score Skindex-29 in MF All MF MF KIR3DL2>1% • Severe global scores for most (68.8%) of the patients at baseline decreasing to 40% or less of the patients from W45 MF KIR3DL2<1% • Severe score reported regardless of KIR3DL2 expression for majority of MF patients at baseline • Seve
Slide 12: TELLOMAK Health Related Quality of Life Conclusions
TELLOMAK Health Related Quality of Life Conclusions • TELLOMAK is a Phase 2 study evaluating lacutamab monotherapy in CTCL. The study showed a robust clinical activity of lacutamab with a favorable safety profile. • Quality of Life assessments in TELLOMAK focused on changes in pruritus and skindex-2
Slide 13: TELLOMAK With Thanks
TELLOMAK With Thanks 53 active sites • USA (17) • France (10) • Germany (8) • Spain (6) • Italy (4) • Belgium (3) • Poland (3) • Austria (2) Thank you to all the patients and their families, our investigators, experts, and site staff Study sponsored by Innate Pharma 13
Slide 14: TELLOMAK Acknowledgment
TELLOMAK Acknowledgment • Germany (8) — KAUFMANN Roland, Universitätsklinikum Frankfurt, Frankfurt • USA (17) — MAGNOLO Nina, Universitaetsklinikum Muenster, Muenster AKILOV Oleg, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania — NICOLAY Jan, Universitaetsmedizin Mannheim GmbH,